A vs IOVA
Agilent Technologies vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
A
Agilent Technologies
70
Buy
VS
IOVA
Iovance Biotherapeutics, Inc.
68
Buy
| Metric | A | IOVA |
|---|
| AI Score |
70
|
68
|
| Price |
$148.45
|
$7.11
|
| P/E Ratio |
29.77×
|
-9.97×
|
| ROE |
19.3%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
53.0%
|
116.3%
|
| Debt / Equity |
0.47×
|
0.06×
|
| Dividend Yield |
0.7%
|
0.0%
|
| RSI (14) |
72.2
|
78.6
|
| Beta |
1.229
|
0.701
|
| Expected Upside |
+0.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for A versus IOVA.
A leads by 2 points.
A scores 70/100 (Buy) versus IOVA at 68/100 (Buy).
A Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 72 is in overbought territory — Technical
- Bollinger bandwidth of 16.1% signals elevated volatility — Risk
IOVA Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 78 -- overbought on the larger timeframe too — Technical